-
Find a Clinical Trial
-
Get Connected
-
Scientific Report
-
Get Involved
-
About MRA
Melanoma survivors are at a 9-fold increased risk of developing another melanoma. Fortunately, in Dr. Rachel Vogel’s previous research, she found that most melanoma survivors adopt vigilant sun safe behaviors to mitigate this increased risk. Unfortunately, while most survivors adopt safer behaviors, 20% of survivors reported a sunburn in the past year and 10% intentionally went outside for a tan – both strong predictors of inappropriate sun exposure. She hopes to disrupt this cycle and to help melanoma survivors live better.
Many try to ignore it, some fight it, and others embrace it, but whatever your strategy – aging is an inescapable fact of life. We get wrinkles and lose muscle mass, cognition starts to decline, and our hair starts to grey or fall out – aging marks all of us in ways both visible and not. Dr. Ashani T. Weeraratna was shocked to discover that older melanoma patients had better outcomes than their younger counterparts when treated with immunotherapy.
Dan needed a miracle. At this point, he’d had six surgeries on his neck, endured radiation therapy, and been enrolled in five clinical trials. Dan’s miracle came in 2006 in the form of an experimental drug, ipilimumab or anti-CTLA4 antibody, that would later be named Yervoy.
The Melanoma Research Alliance (MRA) is pleased to announce its 2018 – 2019 Request for Proposals for preclinical, translational and early clinical research with the power to transform melanoma prevention, detection, staging, and treatment.
The 2018 - 2019 award cycle is anticipated to support at least $9 million in funding. Proposals will be accepted for Established Investigator Awards, Pilot Awards, and Young Investigator Awards.
For Derrick, it all started with headaches. For the first time in his life, this otherwise perfectly healthy father of two, knew something was wrong.
